#Medicaid

A look at the supply chain that results in very high costs for HIV and hepatitis C medications.

Nearly 21 million Americans could lose coverage. Meanwhile, the GOP won’t offer a health care replacement until after 2020.

In fact, antiviral drugs account for nearly 14 percent of total drug costs in the program.

The patient advocacy coalition I Am Essential sent a letter to the HHS spelling out why the plan is dangerous.

Can loads more research dollars stop Alzheimer’s disease by 2025?

A national survey gauges HIV care providers’ views about the Affordable Care Act.

Medi-Cal will soon begin providing treatment access to almost all state-insured patients living with the virus.

The denial rate, which is higher for the privately insured than those with Medicaid or Medicare, is on the rise.

Stocks of drug companies are rising—and that’s not a good sign for consumers.

A new analysis broke down U.S. PrEP use by location and demographics and compared it with corresponding HIV diagnosis rates.

He’ll oversee the FDA, Medicare and Medicaid at a time when soaring drug prices remain a contentious political topic.

More proof that filing treatment access lawsuits can pay off for people with HCV.

States will be able to more easily design programs to increase access to treatment for substance use disorders.

Last week, the president announced that biosimilar drugs would no longer get special incentives on state Medicaid markets.

Sunday, August 27, marks the debut of #NFHAAD. Meet the faith ambassadors now! [VIDEO]

Deep cuts to Medicaid remain, and health insurers could deny coverage to people with preexisting conditions.